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IntroductIon
The obese phenotype is widely heterogeneous: it includes an 
 “at-risk” phenotype and a so-called “metabolically healthy phe-
notype” (MHO) that is present in 10% to over 30% of the obese 
population (1). “At-risk” obese subjects are characterized by insu-
lin resistance and by higher visceral fat and plasma lipid levels 
compared with MHO subjects, although both groups have a high 
BMI and fat mass (2). Low visceral fat (2) and early obesity onset 
(<20 year of age) (3) accounted for 22% and 13% respectively 
of the insulin sensitivity observed in MHO patients, but 65% of 
the phenotype remained unexplained (2). The MHO phenotype 
has been well described in mild obesity (4,5), in postmenopausal 
obesity (3,6), and in a randomly selected  population (7), but not 
in young severely obese people (8).
In the attempt to identify biochemical markers of the MHO 
and “at-risk” obese profiles, we measured several serum adi-
pose and gastrointestinal hormones in a young severely obese 
 population from Southern Italy. The identification of an “at-risk” 
profile, particularly in young subjects, could have important 
implications in their clinical management. In fact, “at-risk” 
obese subjects need aggressive treatment to prevent or delay 
obese-associated metabolic complications, whereas attempts to 
loose weight might be potentially harmful, or not effective in 
MHO individuals (9,10).
Methods and Procedures
study population
We studied 160 unrelated white young adults (mean age ± s.d. = 25.2 ± 9.6 
years; mean BMI [95% confidence interval (CI)] = 44.9 [43.6−46.3] kg/
m2; 65% women) from Southern Italy who had suffered from obesity for 
at least 5 years. The population was recruited at the Obesity Outpatient 
Clinic of the Department of Internal Medicine, Federico II University 
Hospital, Naples, Italy. Clinical, functional, and biochemical data were 
obtained from each patient at the baseline. Secondary causes of obesity 
were excluded, and no patient was an alcohol abuser or under phar-
macological treatment for any disease. We measured: BMI (weight/
height2; kg/m2), waist circumference (WC; cm), blood pressure (systo-
lic blood pressure and diastolic blood pressure; mm Hg) and heart rate 
(beats/min) in each individual after they had been sitting for 5 min; 
we also recorded smoking habits and body composition (fat mass and 
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table 1 Physical and biochemical characteristics (mean and 95% cI) in Mho and “at-risk” severely obese young patients from 
southern Italy
Characteristicsa
MHO (n = 34) M vs. F “At risk” (n = 126) M vs. F MHO vs. “at risk”
Mean 95% CI P valuec Mean 95% CI P valuec P valuec
Age (years)b 22.6 19.7–25.5 Ns 25.8 24.1–27.6 Ns Ns
BMI (kg/m2)b 41.1 38.9–43.3 Ns 46.1 44.5–47.7 Ns 0.003
WC (cm)b 122.5 118.0–127.0 Ns (M) 140.8
(F) 128.6
135.2–146.5
124.8–132.3
<0.0001 Ns
RQ 0.9 0.82–0.89 Ns 0.9 0.85–0.88 Ns Ns
FFM (%) (M) 56.3
(F) 50.0
50.4–62.2
47.9–52.1
0.010 (M) 53.9
(F) 50.2
52.2–55.6
48.9–51.3
0.001 Ns
FM (%)b (M) 43.6
(F) 49.9
37.7–49.6
47.9–52.1
0.010 (M) 46.1
(F) 50.1
44.4–47.8
48.9–51.3
<0.0001 Ns
SBP (mm Hg)b 119.4 117.7–121.1 Ns 122.1 120.5–123.7 Ns Ns
DBP (mm Hg) 77.4 75.7–79.1 Ns 78.7 77.6–79.8 Ns Ns
Heart rate (beats/min) 76.8 74.4–79.2 Ns 78.6 77.5–79.8 Ns Ns
Glucose (mmol/l) 4.1 3.9–4.3 Ns 4.7 4.5–4.9 Ns <0.0001
Total cholesterol (mmol/l) 4.3 3.9–4.7 Ns (M) 4.4
(F) 4.6
4.1–4.7
4.4–4.8
0.041 Ns
HDL cholesterol (mmol/l) (M) 1.0
(F) 1.2
0.8–1.2
1.1–1.3
0.032 (M) 1.0
(F) 1.2
0.9–1.1
1.1–1.3
0.007 Ns
Triglycerides (mmol/l)b 1.0 0.8–1.2 Ns 1.5 1.4–1.7 Ns <0.0001
AST (U/l) (M) 25.9
(F) 18.6
20.6–31.2
17.2–19.9
0.002 (M) 35.1
(F) 23.8
25.4–44.9
20.8–26.8
<0.0001 (F) 0.029
ALT (U/l) (M) 39.3
(F) 20.9
28.7–49.9
18.0–23.9
<0.0001 (M) 52.2
(F) 30.7
41.1–63.2
26.3–35.1
<0.0001 Ns
GGT (U/l)b (M) 29.4
(F) 15.1
20.2–38.7
13.2–17.0
<0.0001 (M) 34.5
(F) 29.3
24.4–44.6
21.4–37.2
0.002 (F) 0.001
FLIb 86.7 81.4–92.1 Ns 94.4 92.7–96.1 Ns <0.0001
Fibrinogen (µmol/l) 11.2 10.5–12.0 Ns 12.0 11.6–12.5 Ns Ns
Creatinine (µmol/l) (M) 79.5
(F) 61.8
70.7–88.4
53.0–62.0
<0.0001 (M) 70.7
(F) 61.8
61.8–79.5
53.0–62.0
<0.0001 (M) 0.042
Urea (mmol/l)b 4.6 4.2–5.0 Ns 5.1 4.9–5.3 Ns 0.039
C-peptide (ng/ml) 2.4 2.1–2.7 Ns (M) 4.4
(F) 4.0
4.0–4.7
3.7–4.4
0.046 <0.0001
Insulin (mIU/l) 8.7 7.8–9.7 Ns 23.9 21.8–26.0 Ns <0.0001
HOMA 1.5 1.4–1.7 Ns (M) 4.5
(F) 3.8
4.0–4.9
3.5–4.1
0.009 <0.0001
Glucagon (ng/ml) 0.96 0.91–1.02 Ns 0.94 0.91–0.97 Ns Ns
Ghrelin (pg/ml) 122.0 104.4–139.7 Ns 116.5 105.8–127.3 Ns Ns
GIP (pg/ml) 61.2 50.8–71.5 Ns 55.1 50.5–59.8 Ns Ns
GLP-1 (ng/ml) 1.1 0.8–1.3 Ns 0.9 0.8–1.1 Ns Ns
IL-6 (pg/ml) 14.1 11.4–16.8 Ns 12.5 11.2–13.7 Ns Ns
TNFα (pg/ml) 39.7 30.5–48.8 Ns 36.7 32.3–41.0 Ns Ns
Leptin (ng/ml) (M) 4.3
(F) 6.9
2.1–6.4
5.6–8.3
0.010 (M) 6.9
(F) 8.2
5.8–7.9
7.3–9.0
Ns (M) 0.023
Adiponectin (µg/ml) 28.0 24.7–31.3 Ns 24.1 22.3–25.8 Ns Ns
L/A ratiob 0.25 0.19–0.31 Ns 0.37 0.32–0.41 Ns 0.003
Adipsin (ng/ml) 592.2 507.9–676.4 Ns 503.3 460.7–545.9 Ns Ns
Visfatin (ng/ml)b 7.6 6.0–9.2 Ns 5.8 5.1–6.5 Ns 0.026
ALT, alanine aminotransferase; AST, aspartate aminotransferase; DBP, diastolic blood pressure; F, females; FLI, fatty liver index; FFM, fat free mass; FM, fat mass; GIP, gastric 
inhibitory peptide; GGT, γ-glutamyl transferase; GLP-1, glucagon-like peptide-1; HOMA, homeostasis model assessment; IL-6, interleukin-6; L/A, leptin/adiponectin ratio; 
M, males; MHO, metabolically healthy obese subjects; Ns, not significant; RQ, respiratory quotient; SBP, systolic blood pressure; TNFα, tumor necrosis factor-α; WC, waist 
circumference.
aReported as mean and 95% confidence interval (CI). bVariables used in the logistic model to assess their association with the “at-risk” characteristic in our obese popula-
tion. cAt Mann–Whitney or Student’s t-test, as appropriate.
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fat free mass using the bioelectrical impedance technique). The physi-
cal and biochemical characteristics of the population are reported in 
Supplementary Table S1 online. A venous blood sample was collected 
from each patient at 8.00 am after an overnight fast. The families of 
all subjects had lived in Southern Italy for at least three generations 
and all subjects gave their informed consent to the study. The research 
was approved by the Ethics Committee of the Faculty of Medicine, 
University of Naples Federico II, and was carried out according to the 
Helsinki II Declaration.
Laboratory investigations
Serum glucose, total cholesterol, high-density lipoprotein cholesterol, 
triglycerides, aspartate aminotransferase, alanine aminotransferase, 
γ-glutamyl transferase (GGT), fibrinogen, creatinine, urea, C-peptide 
and insulin were measured by routine laboratory methods. Insulin resist-
ance was estimated according to the homeostasis model assessment and 
the formula: fasting insulin (mIU/l) × fasting glucose (mmol/l)/22.5. 
We calculated the fatty liver index (FLI) according to the formula 
FLI = (e0.953 × ln (triglycerides) + 0.139 × BMI + 0.718 × ln (GGT) + 0.053 × waist circumference−15.745)/
(1 + e0.953 × ln (triglycerides) + 0.139 × BMI + 0.718 × ln (GGT) + 0.053 × waist circumference−15.745) × 100 
as a measure of hepatic steatosis (11).
Serum glucagon, ghrelin, gastric inhibitory peptide, glucagon-like 
peptide-1, interleukin-6, tumor necrosis factor-α (TNFα), leptin, adi-
ponectin, adipsin, and visfatin were measured by Luminex xMAP Tech-
nology on a BioRad Multiplex Suspension Array System (BioRad, Hemel 
Hempstead, Herts), according to the manufacturer’s instructions. We also 
calculated the leptin/adiponectin (L/A) ratio.
The study population was divided into two groups: MHO individu-
als, i.e., subjects who were “insulin sensitive” and had no more than one 
risk factor (hypertension or dyslipidemia); and “at-risk” individuals, i.e., 
subjects who were “insulin-resistant” with or without other risk factors, 
namely, hypertension, dyslipidemia, and hyperglycemia. A homeostasis 
model assessment index (HI) lower or greater than 1.95 defined insulin 
sensitivity or resistance, respectively (6,12).
statistics
Data are reported as mean ± s.d. or the 95% CI. Angular transformation 
(arcsin of the square root) of the L/A ratio was applied before statisti-
cal analyses. The unpaired Student’s t-test, the Mann–Whitney test or 
the χ2-test were used for between-group comparisons, as appropriate. 
Differences were considered statistically significant at a P level <0.05. 
Binomial logistic regression analysis was used to investigate the asso-
ciation between the biochemical and clinical characteristics and the 
“at-risk” condition, as previously defined. The odds ratio relative to clin-
ically meaningful differences for the continuous variables are reported. 
To explore the possibility of missing a potential association due to the 
loss of information consequent to the introduction of the binary cat-
egorization of the HI in the logistic analysis, a multiple linear regression 
analysis was performed using the continuous HI as dependent variable 
for the same set of independent variables used in the logistic regression 
analysis. Both forward and backward procedures were used for model 
selection and gave concordant results. Statistical analyses were carried 
out with the SPSS package for Windows (ver. 17; SPSS, Chicago, IL).
resuLts
A family history of obesity was recorded in 31.5% indi-
viduals, of concomitant obesity + hypertension + diabetes 
in 53% and hypertension alone in 6.2%. Thirty-four indi-
viduals (21.3%) were classified “MHO”. There were no sig-
nificant differences between “at-risk” and MHO individuals 
regarding sex, smoking habit, and family history of obesity. 
Only 6.3% of insulin-resistant “at-risk” individuals were 
also hyperglycemic. Mild hypertransaminasemia was also 
present in 52/160 (32.3%) of the study population: 37.3% of 
the “at-risk” group and 11.8% of the MHO group (P = 0.004). 
Hypertension (mean systolic blood pressure/diastolic blood 
pressure >133/89 mm Hg) was present in 11% of our “at-risk” 
patients; moreover, these patients also had a higher mean L/A 
ratio and HI values (hypertensive vs. normotensive patients, 
L/A ratio: 0.46 vs. 0.35, P = 0.038; HI: 5.3 vs. 3.9, P = 0.002). 
However, all our hypertensive obese patients belonged to the 
“at-risk” group.
Levels of GGT (women, P = 0.001) and of urea (P = 0.027) 
were higher in the “at-risk” than in the MHO group. The FLI 
was higher in the “at-risk” group (94.4), as expected, given the 
liver involvement, than in the MHO group (86.7) (P < 0.0001). 
Table 1 shows the mean serum levels of adipokines and hor-
mones measured in MHO and “at-risk” individuals together 
with the other physical and biochemical parameters measured 
in this study. The “at-risk” individuals had, at univariate analy-
sis, higher mean levels of BMI (P < 0.0001), leptin (P = 0.039, 
men) and L/A ratio (P = 0.003), and lower mean levels of visfa-
tin (P = 0.026) than the MHO group.
The variables used in the logistic model to assess their asso-
ciation with the “at-risk” phenotype in our obese population 
are indicated in Table 1 (variables “b” labelled). The final model 
showed a Nagelkerke R2 = 0.19, and only two variables were 
retained as significant: the L/A ratio (odds ratio/95% CI = 
1.44/1.07−1.94), and the serum concentration of triglycerides 
(odds ratio/95% CI = 1.87/1.19−2.94). The final multiple lin-
ear regression model resulted in the addition of gender to the 
other significant factors, i.e., the L/A ratio and serum triglyc-
erides. The overall adjusted R2 was equal to 0.195, indicating 
that both the logistic and the multiple linear models are, in 
practice, equivalent.
dIscussIon
The characterization of several serum adipokines and gas-
trointestinal hormones in the young severely obese popula-
tion reported herein suggests that the serum L/A ratio, serum 
triglycerides, male sex, and the HI could be useful markers for 
the diagnosis of “at-risk” obese patients. Based on an almost 
complete absence of traditional risk factors for cardiovascu-
lar and metabolic diseases (1,2,6,13), a variable proportion 
(between 10% and 30%) of obese subjects is classified “MHO”. 
Using an HI <1.95 as classification criterion (3), we found a 
prevalence of 21.3% of MHO patients in our young severely 
obese patients. This prevalence was similar to or lower (from 
24.4% to 31.7%) than those obtained in mild and/or severe 
older obese subjects in other European and non-European 
populations (3,4,7,8,14). Besides the use of different criteria 
to classify MHO, these differences could be explained by the 
different age, female/male ratio, and classes of obesity inves-
tigated. In fact, the prevalence of uncomplicated obesity was 
reported to be higher in a very young (16–29 years) obese 
population than in other age groups, independent of BMI cat-
egory (8). Our patients had been obese for at least 5 years, 
but the MHO group was 3 years younger than the “at-risk” 
group. This finding suggests that juvenile onset obesity rap-
idly progresses toward a more severe phenotype as observed 
in older obese populations (4,5,7,8,14).
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Levels of the two inflammatory markers interleukin-6 and 
TNFα did not differ between the MHO and the “at-risk” 
groups in our obese population. This finding is in agreement 
with some reports (15,16) but not with others (6,7,17). It is 
possible that the discrepancy stems from the young age of the 
population we studied.
The young age of our patients might also explain the rela-
tively low percentage of hypertensive subjects in our popula-
tion. In a previous study of a nonobese male population of our 
geographical area, hypertension was associated with decreased 
insulin sensitivity (18). However, the L/A ratio remained 
significantly higher in the “at-risk” group than in the MHO 
group, also when hypertensive patients were excluded from the 
statistical analysis (0.35 vs. 0.25, P = 0.008). This suggests that 
factors other than hypertension are at play during the onset of 
insulin resistance in young obese subjects. Furthermore, the 
low high-density lipoprotein cholesterol levels in our MHO 
and “at-risk” subjects probably reflects the similar sedentary 
lifestyle of our subjects.
In agreement with a lower hepatic insulin resistance and 
a lower liver fat content in MHO patients observed in post-
menopausal women (19), in the general population (11) and 
by us in a middle-aged obese population (20), the levels of FLI, 
an index of liver steatosis, were higher in “at-risk” individuals 
than in the MHO group (P < 0.0001). This could be due to 
the fact that trapping of free fatty acids is impaired in “at-risk” 
individuals (19). Furthermore, in overweight patients, the L/A 
ratio was reported to be higher in nonalcoholic steatohepati-
tis than in simple steatosis, irrespective of insulin resistance 
(21). In our study, the L/A ratio was not correlated with FLI, 
although the latter was significantly higher in “at-risk” than in 
MHO patients. This observation could be due to the lower sen-
sitivity of FLI compared to liver biopsy, which is not routinely 
performed in severe obesity, in diagnosing liver steatosis (21).
In our study, the serum L/A ratio, serum triglycerides, and 
male sex were the most significant parameters associated 
with “at-risk” obesity; indeed they accounted for 19.5% of the 
insulin-resistant phenotype. The L/A ratio was reported to be 
negatively correlated with insulin sensitivity indexes in a large 
population of nonobese and nondiabetic individuals (22), and 
we previously demonstrated that this ratio contributed to the 
metabolic syndrome in severe obesity (20).
Brochu et al. found that visceral adipose tissue plays a rele-
vant role in insulin resistance insurgence (3). We are unable to 
evaluate the relative effect of this tissue or of the L/A ratio on 
insulin resistance because we did not measure visceral adipose 
tissue in our population. However, the lack of a significant 
association between WC, a rough index of visceral adipos-
ity, and the BMI, an index of total adiposity, with the HI in 
both the logistic and the multiple regression models probably 
indicates that, in this selected population with severe obes-
ity, the L/A ratio is a better marker of “at-risk” obesity than 
either WC or BMI. This observation is supported by the fact 
that the association of WC and BMI with HI becomes statisti-
cally significant (P = 0.031 and P = 0.042, respectively) when 
the adipokines are not included in the model. Consequently, 
the L/A ratio-HI association that we observed is independent 
of both WC and BMI. The apparent discrepancy between our 
findings and those of Brochu et al. is probably due to the dif-
ferences between the two examined populations, namely mean 
age (MHO vs. “at risk”, Brochu et al: 58.0 vs. 58.6 years; our 
data: 22.6 vs. 25.8 years), gender composition, (Brochu et al. 
100% females, in our population 65% females) and underlying 
 physiopathologic conditions (severity of obesity and postmen-
opausal condition) and to different methodological aspects.
In conclusion, we demonstrate that a high serum L/A ratio 
and high levels of serum triglycerides may be markers of “at-
risk” obesity, independent of WC and BMI, in young severely 
obese population.
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